Allogeneic hematopoietic stem cell transplantation for patients with acute leukemia

被引:0
|
作者
Yan Chen [1 ]
Yajing Xu [1 ]
Gan Fu [1 ]
Yi Liu [1 ]
Jie Peng [1 ]
Bin Fu [1 ]
Xiaoyu Yuan [1 ]
Hongya Xin [1 ]
Yan Zhu [1 ]
Qun He [1 ]
Dengshu Wu [1 ]
Yigang Shu [1 ]
Xiaolin Li [1 ]
Xielan Zhao [1 ]
Fangping Chen [1 ]
机构
[1] Department of Hematology,Xiangya Hospital,Central South University
关键词
Leukemia; hematopoietic stem cell transplantation (HSCT); graft-versus-leukemia effect;
D O I
暂无
中图分类号
R733.7 [白血病];
学科分类号
100214 ;
摘要
Objective: The purposes of this study were to assess the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia (AL) and analyze the factors affecting the prognosis of these patients. Methods: The clinical and follow-up data of 93 AL patients (median age, 30 years) undergoing allogeneic HSCT in Xiangya Hospital over the past 12 years were collected, and the potential factors affecting the efficacy and prognosis of allogeneic HSCT patients were determined. Results: Hematopoietic reconstitution was achieved in 90 patients. At the last follow-up, the incidences of severe acute graft versus host disease (aGvHD) and extensive chronic GvHD (cGvHD) were 14.0% and 20.0%, the 3-year cumulative incidence of transplantation related mortality (TRM) and relapse rate were 16.8%±6.1% and 21.3%±6.7%, and the estimated 3-year overall survival (OS) and disease-free survival (DFS) of the patients were 64.6%±5.4% and 56.5%±5.5%, respectively. Univariate analysis indicated that age older than 40 years, HLA mismatch, and severe lung infection within the first 100 days after transplantation were risk factors for severe aGvHD, age older than 40 years, HLA mismatch, severe lung infection within the first 100 days after transplantation, and severe aGvHD were risk factors for TRM, high-risk AL and lack of cGvHD were risk factors for relapse (all P<0.05). Survival estimation showed that HLA mismatch, severe lung infection occurring within the first 100 days post-transplantation, high-risk AL severe aGvHD and lack of cGvHD were risk factors associated with poor prognosis (all P<0.05). Further multivariate analyses revealed that severe lung infection within the first 100 days post-transplantation, severe aGvHD and lack of cGvHD were independent risk factors for unfavorable outcomes (all P<0.05). Conclusions: Allogeneic HSCT can improve the DFS of AL patients, and severe lung infection within the first 100 days post-transplantation, severe aGvHD and lack of cGvHD are independent risk factors affecting the prognosis.
引用
收藏
页码:389 / 396
页数:8
相关论文
共 50 条
  • [1] Allogeneic hematopoietic stem cell transplantation for patients with acute leukemia
    Chen, Yan
    Xu, Yajing
    Fu, Gan
    Liu, Yi
    Peng, Jie
    Fu, Bin
    Yuan, Xiaoyu
    Xin, Hongya
    Zhu, Yan
    He, Qun
    Wu, Dengshu
    Shu, Yigang
    Li, Xiaolin
    Zhao, Xielan
    Chen, Fangping
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (04) : 389 - 396
  • [2] Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation
    Choi, Yunsuk
    Choi, Eun-Ji
    Lee, Jung-Hee
    Lee, Kyoo-Hyung
    Jo, Jae-Cheol
    Park, Han-Seung
    Lee, Yoo Jin
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Lee, Je-Hwan
    [J]. CLINICAL TRANSPLANTATION, 2021, 35 (03)
  • [3] Allogeneic hematopoietic stem cell transplantation for acute leukemia
    Appelbaum, FR
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (01) : 114 - 123
  • [4] Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia
    Levin-Epstein, Rebecca
    Oliai, Caspian
    Schiller, Gary
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (12)
  • [5] Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia
    Rebecca Levin-Epstein
    Caspian Oliai
    Gary Schiller
    [J]. Current Treatment Options in Oncology, 2018, 19
  • [6] Allogeneic hematopoietic stem cell transplantation for acute lymphocytic leukemia
    Ren, HY
    Chen, H
    Huang, XJ
    Xu, LP
    Zhang, Y
    Liu, DH
    Guo, NL
    Lu, DP
    [J]. BONE MARROW TRANSPLANTATION, 2003, 31 : S174 - S174
  • [7] Allogeneic hematopoietic stem cell transplantation for acute leukemia, chronic leukemia, and myelodysplasia
    Popplewell, L
    Forman, SJ
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (05) : 987 - +
  • [8] Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation
    Kurosawa, Shuhei
    Toya, Takashi
    Kishida, Yuya
    Nagata, Akihito
    Yamada, Yuta
    Konishi, Tatsuya
    Kaito, Satoshi
    Yoshifuji, Kota
    Matsuyama, Naoki
    Shirane, Shuichi
    Uchida, Tomoyuki
    Inamoto, Kyoko
    Igarashi, Aiko
    Najima, Yuho
    Muto, Hideharu
    Kobayashi, Takeshi
    Doki, Noriko
    Kakihana, Kazuhiko
    Sakamaki, Hisashi
    Ohashi, Kazuteru
    [J]. LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 3006 - 3009
  • [9] The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia
    Kebriaei, Partow
    Poon, L. M.
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2012, 7 (02) : 144 - 152
  • [10] Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia
    Poon, L. M.
    Bassett, R., Jr.
    Rondon, G.
    Hamdi, A.
    Qazilbash, M.
    Hosing, C.
    Jones, R. B.
    Shpall, E. J.
    Popat, U. R.
    Nieto, Y.
    Worth, L. L.
    Cooper, L.
    De Lima, M.
    Champlin, R. E.
    Kebriaei, P.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 (05) : 666 - 670